Belgian gene therapy player aims for $99M in IPO; Heron launches Phase II trials of long-acting pain candidate;

> Heron Therapeutics ($HRTX) announced the launch of the Phase II clinical trial of its lead candidate for the prevention of post-operative pain. It utilizes the company's proprietary drug delivery technology and is a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam. More

> Belgium's gene therapy biotech Celyad announced the terms of its IPO. It aims to raise $99 million through the offer of 1.4 million shares priced at $70.98 per unit. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.